A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nabpaclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer

被引：0

作者：

Vincent, Picozzi ^{[1
]}

Vaibhav, Sahai ^{[2
]}

Diane, Simeone ^{[2
]}

Caio, Rocha Lima ^{[3
]}

Allyson, Ocean ^{[4
]}

Philip, Philip ^{[5
]}

Wasif, Saif ^{[6
]}

Aparna, Kalyan ^{[7
]}

Michael, Ondovik ^{[8
]}

Jack, Shiansong Li ^{[8
]}

Chrystal, Louis ^{[8
]}

机构：

[1] Virginia Mason, Seattle, WA USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Gibbs Canc Ctr, Res Inst, Spartanburg, SC USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Karmanos Canc Ctr, Detroit, MI USA

[6] Tufts Med Ctr, Boston, MA USA

[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[8] Celgene Corp, Summit, NJ USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-231

引用

页数：2

共 50 条

[41] Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
Lee, J.
Kang, W. K.
Kwon, J. M.
Oh, S. Y.
Lee, H. R.
Kim, H. J.
Park, B. B.
Lim, H. Y.
Han, M. J.
Park, J. O.
Park, Y. S.
ANNALS OF ONCOLOGY, 2007, 18 (01) : 88 - 92
[42] TOXICITY STUDY OF GEMCITABINE, OXALIPLATIN AND BEVACIZUMAB THEN 5-FLUOROURACIL, OXALIPLATIN, BEVACIZUMAB AND RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER
O'Dwyer, P. J.
Sun, W.
Harlacker, K.
Giantonio, B.
Rosato, E.
Ginsberg, G.
Kochman, M.
Drebin, J.
Metz, J.
ANNALS OF ONCOLOGY, 2010, 21 : 44 - 44
[43] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancer
Bleiberg, H.
Vandebroek, A.
Deleu, I.
Vergauwe, P.
Kalantari, H. Rezaei
D'Haens, G.
Paesmans, M.
Peeters, M.
Efira, A.
Humblet, Y.
ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21
[44] Oxaliplatin/5-FU chemotherapy without leucovorin in metastatic colorectal cancer.
Shim, BY
Cho, HJ
Yang, JM
Kim, HJ
Kim, JK
Kim, HK
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 302S - 302S
[45] Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
Arkenau, Hendrik-Tobias
Graeven, Ullrich
Kubicka, Stephan
Grothey, Axel
Englisch-Fritz, Christina
Kretzschmar, Albrecht
Greil, Richard
Freier, Werner
Seufferlein, Thomas
Hinke, Axel
Schmoll, Hans-Joachim
Schmiegel, Wolff
Porschen, Rainer
CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 60 - 64
[46] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
Andric, Z.
Murtezani, Z.
Kovcin, V
Gutovic, J.
Kostic, S.
ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
[47] A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer
Lubner, Sam J.
LoConte, Noelle K.
Holen, Kyle D.
Schelman, William
Thomas, James P.
Jumonville, Alcee
Eickhoff, Jens C.
Seo, Songwon
Mulkerin, Daniel L.
CLINICAL COLORECTAL CANCER, 2010, 9 (03) : 157 - 161
[48] A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
Ryan, DP
Clark, JW
Kulke, MH
Fuchs, CS
Earle, CC
Enzinger, PC
Stuart, K
Catarius, KJ
Winkelmann, J
Mayer, RJ
CANCER INVESTIGATION, 2003, 21 (04) : 505 - 511
[49] Interim results of a weekly, metronomic dos ng of pac itaxel, oxaliplatin, leucovorin, 5-FU (POLF) in the treatment of metastatic pancreatic cancer (PC)
Chue, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[50] Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer
Chiara, S
Nobile, MT
Gozza, A
Taveggia, P
Heouaine, A
Pastrone, I
Percivale, PL
Lionetto, R
Sanguineti, O
Rosso, R
ANTICANCER RESEARCH, 2004, 24 (01) : 355 - 360

← 1 2 3 4 5 →